Alternatives For Reducing Relapse Rate When Switching From Natalizumab To Fingolimod In Multiple Sclerosis.
- Fragoso, Yara Dadalti
- Adoni, Tarso
- Alves-Leon, Soniza Vieira
- Apostolos-Pereira, Samira Luisa
- de Araujo, Yuna Ribeiro
- Becker, Jefferson
- Bidin Brooks, Joseph Bruno
- Correa, Eber Castro
- Damasceno, Alfredo
- de Albuquerque Damasceno, Carlos Augusto
- Ferreira, Maria Lucia B
- da Gama, Paulo Diniz
- Diniz da Gama, Rodrigo Assad
- Gomes, Sidney
- Magno Goncalves, Marcus Vinicius
- Grzesiuk, Anderson Kuntz
- Nunes Machado, Suzana Costa
- da Cunha Matta, Andre Palma
- Mendes, Maria Fernanda
- Goncalves Jube Ribeiro, Taysa Alexandrino
- da Rocha, Cristiane Franklin
- Ruocco, Heloisa Helena
- Sato, Henry
- Simm, Renata Faria
- Tauil, Carlos Bernardo
- Ferreira Vasconcelos, Claudia Cristina
- Ferreira Vieira, Vera Lucia
DOIAbstract
Natalizumab is a therapeutic option for treating multiple sclerosis (MS) and is particularly efficacious for patients with highly active disease. A long washout period has been recommended between withdrawal of natalizumab and start of fingolimod (another option for treating MS). This long washout period has been associated with a significant increase in MS activity. In the present study, a group of 96 patients who were switched from natalizumab to fingolimod had short washout periods between drugs, or monthly corticosteroid pulse therapy if longer washout periods were recommended. This therapeutic approach led to the lowest reported relapse rate so far, among patients with MS switching from natalizumab to fingolimod (8.3%). No complication...
Add to ORKG